Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005836 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005836: Completed Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00005836 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005836, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent or refractory ovarian epithelial cancer or primary peritoneal cancer that has not responded to platinum-based chemotherapy.
Interventions
- DRUG oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02 |
| Est. Completion | 2004-07 |
| Phase | Phase 2 |
What the finished NCT00005836 record still lists
NCT00005836 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which oxaliplatin is the first listed.
NCT00005836 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005836 about?
NCT00005836 is a clinical study titled "Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent or refractory ovarian epithelial cancer or primary peritoneal cancer that...
What is the current status of trial NCT00005836?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-02. Estimated completion is 2004-07.
What interventions are being tested in trial NCT00005836?
The interventions under investigation include: oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00005836?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia